首页> Journal of Clinical Oncology> Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Gradishar WJ

作者： Gradishar WJ ^[1] ; Krasnojon D ; Cheporov S

作者单位： Northwestern University, Breast Oncology, Division of Hematology/Oncology, Department of Medicine ^[1]

发布时间 2018-10-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览10

Journal of Clinical Oncology

2009年27卷22期

3611-3619页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览10

点击下载本期目录封面

Journal of Clinical Oncology

2009年27卷22期

3611-3619页

检索历史清除

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

检索历史清除